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Abstract: Objective: The factors associated with persistent delirium, in contrast to resolved delirium,
have not been studied well. The aim of our present study was to identify the factors associated with
delirium resolution as measured by the Memorial Delirium Assessment Scale (MDAS) and functional
improvement as measured by the Karnofsky Performance Status (KPS) scale. Method: All subjects were
recruited from psychiatric referrals at the Memorial Sloan Kettering Cancer Center (MSKCC). The two
study instruments were performed at baseline (T1), at 2-3 days (T2), and at 4-7 days (T3). Subjects
with persistent delirium were compared to those with resolved delirium in respect to sociodemographic
and medical variables. Results: Overall, 26 out of 111 patients had persistent delirium. These patients
were older, predominantly male, and had more frequently preexisting comorbid dementia. Among cancer
diagnoses and stage of illness, brain cancer and terminal illness contributed to persistent delirium or
late response, whereas gastrointestinal cancer was associated with resolved delirium. Among etiologies,
infection responded late to delirium management, usually at one week. Furthermore, delirium was more
severe in patients with persistent delirium from baseline through one week. At baseline, MDAS scores
were 20.1 in persistent delirium compared to 17 to 18.8 in resolved delirium (T2 and T3), and at one week
of management (T3), MDAS scores were 15.2 and 4.7 to 7.4, respectively. At one week of management,
persistent delirium manifested in more severe impairment in the domains of consciousness, cognition,
organization, perception, psychomotor behavior, and sleep-wake cycle. In addition, persistent delirium
caused more severe functional impairment. Significance of results: In this delirium sample, advanced age
and preexisting dementia, as well as brain cancer, terminal illness, infection, and delirium severity con-
tributed to persistent delirium or late response, indicating a prolonged and refractory course of delirium,
in addition to more severe functional impairment through one week of management.
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ABSTRACT
Objective: The factors associated with persistent delirium, in contrast to resolved delirium, have
not been studied well. The aim of our present study was to identify the factors associated with
delirium resolution as measured by the Memorial Delirium Assessment Scale (MDAS) and
functional improvement as measured by the Karnofsky Performance Status (KPS) scale.
Method: All subjects were recruited from psychiatric referrals at the Memorial Sloan
Kettering Cancer Center (MSKCC). The two study instruments were performed at baseline
(T1), at 2–3 days (T2), and at 4–7 days (T3). Subjects with persistent deliriumwere compared to
those with resolved delirium in respect to sociodemographic and medical variables.
Results:Overall, 26 out of 111 patients had persistent delirium. These patients were older,
predominantly male, and had more frequently preexisting comorbid dementia. Among
cancer diagnoses and stage of illness, brain cancer and terminal illness contributed to
persistent delirium or late response, whereas gastrointestinal cancer was associated with
resolved delirium. Among etiologies, infection responded late to delirium management,
usually at one week. Furthermore, delirium was more severe in patients with persistent
delirium from baseline through one week. At baseline, MDAS scores were 20.1 in persistent
delirium compared to 17 to 18.8 in resolved delirium (T2 and T3), and at one week of
management (T3), MDAS scores were 15.2 and 4.7 to 7.4, respectively. At one week of
management, persistent delirium manifested in more severe impairment in the domains of
consciousness, cognition, organization, perception, psychomotor behavior, and sleep–wake
cycle. In addition, persistent delirium caused more severe functional impairment.
Significance of results: In this delirium sample, advanced age and preexisting dementia,
as well as brain cancer, terminal illness, infection, and delirium severity contributed to
persistent delirium or late response, indicating a prolonged and refractory course of
delirium, in addition to more severe functional impairment through one week of
management.
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INTRODUCTION
Delirium is a common condition in the course of hos-
pitalization depending on the age of the patient and
the severity of their illness (Francis et al., 1990;
Voyer et al., 2007). The occurrence of delirium varies
depending on its presentation. On admission, in
older patients the prevalence rate varies between
14 and 24% and in the course of hospitalization the
incidence rate is between 6 and 56% (Bucht et al.,
1999; Lipowski, 1989). In the general hospital set-
ting, the incidence of delirium ranges between 15
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and 30% of patients, in the hospitalized elderly 10–
40% (Bucht et al., 1999; Lipowski, 1989), in patients
with cancer 57–85%, and in terminal illness up to
85% (Bond et al., 2006; Breitbart & Strout, 2000;
Massie et al., 1983). Furthermore, delirium can
have long-term consequences and is associated with
poor functional outcome, increased morbidity and
mortality, and prolonged hospitalization (Inouye,
1998; 2006).
Several medical conditions have been identified as
risk factors for delirium relevant to a specific cancer
setting: low albumin levels, bone metastases, and
the presence of hematological malignancy (Ljubisavl-
jevic & Kelly, 2003). Medications represent another
risk factor for developing delirium, where the admin-
istration of benzodiazepines, corticosteroids, and
opioids has been associatedwith incidence of delirium
(Gaudreauet al., 2005;Rothberget al., 2013).Another
etiology representing a risk factor for delirium is
hypoxic illness,whichhasbeen recognized to interfere
with the reversibility of delirium,whereas the admin-
istration of opioids or dehydrationhas been associated
with reversible delirium (Lawlor et al., 2000a).
In a study on the occurrence and persistence of
delirium symptoms (Levkoff et al., 1992), advanced
age and cognitive impairment have been identified
as a risk factor for increased incidencewithin a popu-
lation. Persistence of delirium has been documented
at three and six months after discharge from the hos-
pital, leading to the conclusion that delirium may be
a common disorder during the course of hospitaliz-
ation and is much less transient than previously
thought. Several studies have documented persistent
delirium symptoms, some lasting for six months and
longer (Kiely et al., 2006; McCusker et al., 2001;
2003). Furthermore, an association between length
and persistence of delirium symptoms and functional
recovery has been documented. Moreover, persistent
delirium has been shown to be a predictor of greater
mortality (Kiely et al., 2009; Lee et al., 2011). In con-
trast, the persistence of delirium symptoms for less
than two weeks has been associated with excellent
functional recovery (Kiely et al., 2006), and resolved
delirium is associated with decreased mortality
(Kiely et al., 2009). Another factor contributing to
worse delirium outcomes is the severity of delirium,
with more severe episodes leading to more serious
outcomes (Marcantonio et al., 2002).
Although there is evidence for the persistence of
delirium symptoms and consequent functional sta-
tus, our knowledge of risk factors and persistence of
delirium in the more acute setting remains limited.
In order to further explore these issues in a hospital
setting, we performed an analysis that assessed the
sociodemographic and medical variables associated
with prolonged and refractory delirium.
METHODS
Subjects
All subjects were referred for delirium management
to the Memorial Sloan Kettering Cancer Center
(MSKCC) Psychiatry Service from July of 2004 to
June of 2006. The MSKCC is a 470-bed, private hos-
pital specializing in the treatment of cancer and has
an average of 20,000 admissions annually. Its consul-
tation–liaison psychiatry service performs more
than 2,000 consultations each year.
All patients included in our study met the criteria
for diagnosis of delirium according to the Diagnostic
and Statistical Manual of Mental Disorders (4th ed.,
text revision) (DSM–IV–TR) (American Psychiatric
Association, 2000). Exclusion criteria were an
inability to comply with delirium assessment, objec-
tions on the part of the patient or family to taking
medication or to treatment of delirium with any
antipsychotic, and imminent death. All patients
and families gave their verbal consent. For patients
with a limited capacity to provide consent due to de-
lirium, the primary caregiver provided verbal con-
sent with the patient’s present.
Clinical data were recorded in an MSKCC Psy-
chiatry Service clinical database approved by the in-
stitutional review board, and a waiver was obtained
for future analysis.
Measurements
Sociodemographic andmedical variables such as age,
sex, cancer diagnosis, stage of cancer (localized,
metastatic, or terminal), psychiatric diagnosis, pre-
existing dementia, presence of brain metastases,
and delirium etiology were collected at baseline
assessment and reevaluated during the observation
period.
Delirium severity was assessed with the Memorial
Delirium Assessment Scale (MDAS), a 10-item,
4-point clinician-rated scale (range 0–30) (Breitbart
et al., 1997). MDAS item scores range from 0 to 3
(0 ¼ absent, 1 ¼mild, 2 ¼moderate, and 3 ¼ severe
in presentation). It provides clear instructions on
the rating process and defines the severity of present-
ing symptoms. Scale items assess such aspects of
delirium symptomatologyas (1) a disturbance in arou-
sal and level of consciousness, (2) impaired cognitive
functioning, (3) weakened psychomotor activity, and
(4) disturbed sleep–wake cycle. MDAS scores greater
than10have been validated to identify the presence of
delirium. In contrast, resolution of delirium is ident-
ified by MDAS scores equal to or less than 10 (Kaz-
mierski et al., 2008; Lawlor et al., 2000b).
Level of functioning was assessed with the Kar-
nofsky Performance Status (KPS) scale, which
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indicates physical performance ability, and was devel-
oped particularly for cancer patients (Karnofsky &
Burchenal, 1949). Scale scores range from 10 to 100,
and lower scores indicate a higher degree of functional
impairment and more severe illness (Appendix 1).
Procedures
In accordancewith the guidelines for management of
delirium promulgated by the American Psychiatric
Association (Trzepacz et al., 1999), environmental
and psychopharmacological interventions were
utilized. In addition to such environmental inter-
ventions as providing a safe environment and fre-
quent reorientation, antipsychotic medications were
also initiated upon diagnosis of delirium and
subsequently adjusted, with modifications deter-
mined by clinical response. The standard approach
is to manage delirium with antipsychotic medication
and continue the necessary medical treatment, with
the use of medications that can be classified as risk
factors for delirium (e.g., opiates and corticosteroids).
Underlying reversible causes such as infections were
also treated.
The MDAS, KPS scoring, and side-effect rating
were performed at baseline (T1), repeated at 2–3
days (T2), and at 4–7 days (T3). The observation
periods ended after seven days, and patients were
continued on antipsychotic medications as necessary.
Statistical Analysis
Analyses for the trial were performed with the Stat-
istical Package for the Social Sciences (SPSS, v. 20),
a statistical software package for Windows. Our pri-
mary interest was persistent delirium in contrast to
resolved delirium in respect to sociodemographic
and medical variables. The secondary interests
were delirium severity and the phenomenology of
delirium as described by total MDAS score and
MDAS subscores. The dataset was defined as subsets
representing persistent delirium, resolved delirium
at T2, and resolved delirium at T3. Descriptive stat-
istics were run in order to describe the sociodemo-
graphic and medical variables.
A number of statistical tests were employed in our
analysis. For parametric data on an interval scale
(e.g., comparison of age between groups), a t test for
independent samples was implemented. For non-
parametric data (e.g., MDAS or KPS scores during
the observation period), Friedman’s test for repeated
measures was employed for dependent measures,
and the Kruskal–Wallis test was utilized for inde-
pendent measures (e.g., MDAS or KPS scores
between groups). Pearson’s chi-square (x2) was im-
plemented for categorical data (e.g., evaluation of
cancer diagnoses and etiologies contributing to delir-
ium). Afterward, alpha (a) was corrected using the
Bonferroni method, and the significance level for a
was set at p , 0.05.
RESULTS
Baseline Characteristics
Overall, some 111 patients with delirium were
retrieved, and 26 of these (23.4%) had persistent
delirium (Table 1). Most patients (52, 47%) achieved
delirium resolution within 48 to 72 hours.
Differences with respect to sociodemographic and
medical variables between persistent and resolved
delirium at T2 and T3 were as follows. Patients
with persistent delirium were predominantly male
and older than those with resolved delirium at T2
or T3, and preexisting dementia contributed to per-
sistent delirium. In contrast, the absence of dementia
was associated with faster recovery. Furthermore,
factors contributing to late response or persistent de-
lirium included the presence of brain cancer and
terminal cancer. One fifth of patients with persistent
delirium had brain cancer, in contrast to 3.8–12.1%
with resolved delirium at T2 or T3. Terminal illness
was present in 20% with persistent delirium and
about 33%with resolved deliriumat oneweek, in con-
trast to 3.8% of those with resolved delirium at T2.
Thus, the absence of brain cancer or terminal illness
were associated with faster recovery with 72 hours of
management. Among the etiologies, infection was
usually associated with a later response to delirium
management within one week.
DescriptionofDeliriumSeverityandPhenomenology
in Persistent and Resolved Delirium at Baseline
At baseline, delirium was more severe in patients
with persistent delirium. The phenomenology of
delirium as measured by the MDAS subitems was
not much different. Marginal differences existed in
the domains of short-term memory, organization,
psychomotor behavior, and sleep–wake cycle.
Patients with persistent delirium were slightly
more impaired than patients with resolved delirium
at T2 or T3. There were no differences with respect
to the domains of consciousness, orientation, concen-
tration, attention, perception, or delusions (see
Table 3).
Management Characteristics and Course of
Delirium
In both persistent and resolved delirium at T2 and
T3, MDAS scores improved over the course of man-
agement. However, differences existed in MDAS
scores at baseline, T2, and T3 (Table 2). Patients
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Table 1. Baseline characteristics of persistent and resolved delirium at T2 and T3
Persistent Delirium
(n ¼ 26)
Resolved Delirium at T2
(n ¼ 52)
Resolved Delirium at T3
(n ¼ 33) p
Age 71.3 (46–86, SD 13.6) 62.7 (23–83, SD 14.8) 65.6 (32–89, SD 12.7) 0 .009a
Gender, in % 0.034b
Male 80.8 51.9 51.5
Female 19.2 48.1 48.5
Preexisting dementia,
in %
42.3 7.7 21.2 0.001b
Brain metastasis, in % 7.7 5.8 15.2 0.364b
Cancer diagnoses, in %
Brain 23.1 3.8 12.1 0.030b
Gastrointestinal 7.7 23.1 36.4 0.042b
Genitourinary 7.7 11.5 6.1 0.697b
Gynecological 11.5 9.6 6.1 0.766b
Head and neck 7.7 5.8 6.1 1.0b
Lung 23.1 23.1 18.2 0.872b
Sarcoma 3.8 11.5 3 0.286b
Other 15.0 12.6 12 0.322b
Stage of cancer, in %
Localized 45.8 34.6 27.3 0.500b
Advanced 33.3 57.7 42.4 0.068b
Terminal 20.8 7.7 30.3 0.023b
Etiologies, in %
Opioids 88.5 88.5 87.9 1.0b
Corticosteroids 57.7 40.4 48.5 0.356b
Hypoxia 42.3 34.6 36.4 0.845b
Infection 19.2 15.4 42.4 0.019b
CNS disease 15.4 9.6 15.2 0.711b
Other CNS disease 23.1 11.5 27.3 0.159b
Other medication 88.2 92.3 81.8 0.074b
Other 81.2 82.7 78.8 0.950b
Total number of
etiologies
5.2 (3–7, SD 0.9) 4.8 (3–7, SD 1) 5.2 (3–8, SD 1) 0.087c






Table 2. Management characteristics of persistent and resolved delirium at T2 and T3 (medication doses
administered at T3, MDAS, KPS scores and delirium resolution at baseline, T2, and T3)
Persistent Delirium
(n ¼ 26)
Resolved Delirium at T2
(n ¼ 52)







Haloperidol (n ¼ 35) 3.7 (1–8, SD 2.2) 5.0 (1–8, SD 2.4) 5.4 (1–16, SD 5.0) 0.470
Risperidone (n ¼ 32) 1.5 (1–2, SD 0.5) 1.1 (0.5–2, SD 0.6) 1.4 (0.25–3, SD 0.9) 0.453
Olanzapine (n ¼ 22) 7.9 (2.5–15, SD 5.3) 5.5 (2.5–15, SD 3.3) 4.2 (2–5, SD 1.4) 0.515
Aripiprazole (n ¼ 22) 13.0 (10–20, SD 4.5) 18.2 (10–30, SD 6.0) 24.0 (20–30, SD 5.5) 0.025
MDAS at baseline 20.1 (13–30, SD 4.4) 17.0 (11–29 (SD 4.5) 18.8 (11–27 (SD 4.4) 0.080
T2 16.3 (11–25, SD 4.5) 6.5 (1–10, SD 2.3) 13.2 (11–24, SD 2.9) ,0.001
T3 15.2 (11–23, SD 4.6) 4.7 (1–10, SD 2.5) 7.4 (1–10, SD 2.2) ,0.001
KPS score at baseline 23.1 (10–30, SD 6.2) 25.8 (20–40, SD 6.10 22.1 (20–30, SD 5.7) 0.015
T2 23.5 (10–30, SD 6.9) 34.4 (20–60, SD 11.4) 23.6 (20–40, SD 10.9) ,0.001
T3 26.2 (10–40, SD 9.4) 39.8 (10–70, SD 13.5) 27.6 (20–50, SD 13.2) ,0.001
MDAS ¼Memorial Delirium Assessment Scale; KPS ¼ Karnofsky Performance Status; SD ¼ standard deviation.
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Table 3. MDAS mean subscores at baseline and T3
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with persistent delirium had a more severe con-
dition at baseline and through one week. In persist-
ent delirium, MDAS scores improved from a
baseline of 20.1 to 16.3 and 15.2 ( p , 0.001) at T3,
in resolved delirium at T2 from a baseline of 17.0
to 6.5 and 4.7 at T3 ( p , 0.001), and in resolved
delirium from a baseline of 18.8 to 13.2 and 7.4
( p , 0.001).
Medication doses were comparable between
groups and medications. When haloperidol, risperi-
done, and olanzapine were administered, the mean
dose at T3 was not different between the persistent
and resolved delirium groups. Only with aripiprazole
administration was the dose higher in patients with
resolved delirium, particularly for those achieving
delirium resolution at T3.
Functional status as measured by KPS score
improved in both persistent and resolved delirium;
however, persistent delirium caused more severe
functional impairment. In persistent delirium at
T2, KPS scores improved marginally from 23.1 to
23.5 at T2 and 26.2 at T3 ( p , 0.015), in those with
resolved delirium at T2 from 25.8 to 34.4 and 39.8
( p , 0.001), and in resolved delirium at T3 from
22.1 to 23.6 at T2 and 27.6 ( p , 0.001). At baseline,
KPS scores were only marginally different; however,
KPS scores at T2 and T3 improved more in patients
with resolved delirium, indicating superior func-
tional recovery.
Delirium Phenomenology in Persistent and
Resolved Delirium at One Week of Management
At one week, the differences between persistent and
resolved delirium were more prominent and existed
across MDAS subscores (Table 3). In persistent
delirium, the disturbance of consciousness was
more pronounced; orientation, short-term memory,
concentration, attention, and level of organization
were more severely impaired; perceptual disturb-
ancesanddelusionsweremore severe; andpsychomo-
tor abnormalities and sleep–wake cycle disturbances
worsened.
DISCUSSION
These results indicate that advanced age, preexisting
dementia, brain cancer, terminal illness, infection,
and delirium severity are factors that interfere with
the resolution of delirium and contribute to a prolon-
ged and refractory course of the condition, and they
can cause functional impairment with up to one
week of management with antipsychotic medi-
cations.
Previous studies have found contradictory results
with respect to the occurrence and persistence of
delirium in dementia. While some authors demon-
strated an increased occurrence in advanced age as
well as cognitive impairment and persistence of de-
lirium symptoms at several months after hospital
discharge, and concluded that delirium may be
more common during the course of hospitalization
and much less transient than formerly accepted
(Kiely et al., 2006; Levkoff et al., 1992; Levkoff &
Marcantonio, 1994; Levkoff et al., 1994; McCusker
et al., 2001; 2003), other investigators were not able
to find an association between dementia and prolon-
ged delirium (Kelly et al., 2001; Koponen et al., 1989;
Manos &Wu, 1997). However, the absence of demen-
tia was associated with complete reversal of all delir-
ium symptoms and a better outcome (Camus et al.,
2000; Inouye et al., 2007).
Among the studies documenting an interaction be-
tween length and persistence of delirium symptoms
and functional recovery, the persistence of delirium
symptoms for less than two weeks was associated
with excellent functional recovery (Kiely et al.,
2006). Advanced age and preexisting dementia.
which have also been identified as risk factors for de-
lirium (Ljubisavljevic & Kelly, 2003) and have been
associated with persistence of delirium, may have
an impact on the course of delirium and outcome,
and can result in a prolonged and refractory course,
even when concomitant to active management with
antipsychotics. In contrast, the absence of dementia
has been associated with complete reversal of delir-
ium symptoms (Camus et al., 2000; Inouye et al.,
2007). Due to the severe consequences that persist-
ent delirium symptoms and unmanaged delirium
can have, more awareness of this population and
different clinical approaches may be required. For
one thing, this population may require more rigorous
screening for delirium and more proactive manage-
ment of the symptoms of delirium until remission.
In addition, not only is dementia a risk factor for
persistent delirium, but it has been identified as
the leading risk factor for developing delirium. Two
thirds of cases with delirium occurred in patients
with dementia (Cole, 2004), and dementia was found
to increase the risk of becoming delirious by 40%
(McNicoll et al., 2003). Also, deliriumhas been shown
to increase the risk of being diagnosed with dementia
in patients with no known premorbid dementia
(Rahkonen et al., 2000), to accelerate cognitive
decline in dementia (Fong et al., 2009a), and has
been associated with poor functional outcomes, in-
creasedmorbidity andmortality, as well as prolonged
hospitalization (Inouye, 1998).
From this analysis, we found that patients with
persistent and resolved delirium were not different
with respect to various sociodemographic and medi-
cal variables. A higher proportion of male patients
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had persistent delirium, and an increased proportion
of brain cancer or terminal illness was documented in
persistent delirium or late response, whereas gastro-
intestinal cancer was associated with faster delirium
resolution. Furthermore, delirium was more severe
in those with persistent delirium. By itself, it was
not surprising that delirium severity or brain cancer
would predict persistent delirium and contribute to
persistent delirium, as has previously been indicated
(Breitbart et al., 2002; Marcantonio et al., 2002).
Among the etiologies contributing to delirium in the
cancer setting, opioids, corticosteroids, and benzo-
diazepines have been identified as risk factors (Gau-
dreau et al., 2005). This result suggested that they
may contribute to the occurrence of delirium, as opi-
ates and corticosteroids were among themost frequent
causes of multifactorial delirium in this sample.
However, they did not interfere with delirium resol-
ution. In contrast to previous findings indicating that
hypoxic illness may be a factor that interferes with
the reversibility of delirium (Lawlor et al., 2000a),
hypoxia has not been associated with persistent delir-
ium. However, infection has been found to contribute
to a late response at one week of management.
The functional status at baseline was similar be-
tween patients with persistent and resolved delirium.
In the course of management with antipsychotics,
patients with persistent deliriumwere more function-
ally impaired throughout, indicating that persistent
delirium also has an impact on level of functioning.
Different dosing regimens contributing to persist-
ent delirium in contrast to resolved delirium was not
found, except with aripiprazole. Antipsychotic dosing
was not different for haloperidol, risperidone, and
olanzapine. When aripiprazole was administered,
the dose at T3 was higher in patients with resolved
delirium. With respect to the greater sensitivity to
side effects in patients with advanced age and de-
mentia, this difference may have only a small effect
(Alexopoulos et al., 2004). In particular, the fact
that the pharmacodynamics and receptor occupancy
for 13- and 20-mg doses of aripiprazole may be simi-
lar would render this difference negligible (DeLeon
et al., 2004;Taylor, 2003).
A number of strengths and limitations of this
analysis can be noted. The delirium database con-
tains clinical data on the treatment of delirium
with haloperidol, risperidone, aripiprazole, and olan-
zapine. Data collection was prospective. Delirium
and contributing etiologies were systematically eval-
uated and documented. All subjects were assigned
naturalistically to a medication, and this assignment
was not random. The number of subjects with demen-
tia was rather low. The etiology of dementia was not
differentiated due to the limited number of patients
with delirium and dementia. It was not possible to
obtain a baseline assessment of the level of cognitive
dysfunction due to the naturalistic design of the data
collection and long-lasting persistence of delirium
symptoms in this population. All subjects had cancer
diagnoses, and the generalizability of our results
to the noncancer population remains to be studied.
The use of antipsychotics in themanagement of delir-
ium is not approved by the regulatory agencies, and
the use of antipsychotics in elderly patients with de-
mentia carries a black-box warning of increased risk
of death (Jeste et al., 2008; Schneider et al., 2005).
The utilization of antipsychotics in the management
of delirium has been debated (Fong et al., 2009b).
Considering the finding of lower delirium resolution
rates in advanced age and preexisting dementia, a
longer observation period would have been favorable.
Despite these limitations, our results may provide
further insight into advanced age, dementia, and
brain pathology with respect to delirium phenomen-
ology and in regard to the course of delirium in
patients actively managed with antipsychotics.
In summary, advanced age and preexisting de-
mentia, as well as the presence of brain cancer, term-
inal illness, infection, and delirium severity were
associated with a prolonged and refractory course of
delirium or late response and lower functional status
at one week of management with antipsychotics.
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Appendix 1. Karnofsky Performance Status Scale: Definitions, ratings (%), and criteria (Karnofsky & Burch-
enal, 1949)
Able to carry on normal activity and to work;
no special care needed.
100 Normal; no complaints; no evidence of disease.
90 Able to carry on normal activity; minor signs or symptoms of
disease.
80 Normal activity with effort; some signs or symptoms of
disease.
Unable to work; able to live at home and care
for most personal needs; varying amount of
assistance needed.
70 Cares for self; unable to carry on normal activity or do active
work.
60 Requires occasional assistance, but is able to care for most of
his personal needs.
50 Requires considerable assistance and frequent medical care.
Unable to care for self; requires equivalent of
institutional or hospital care; disease may be
progressing rapidly.
40 Disabled; requires special care and assistance.
30 Severely disabled; hospital admission is indicated, though
death not imminent.
20 Very sick; hospital admission necessary; active supportive
treatment necessary.
10 Moribund; fatal processes progressing rapidly.
0 Dead.
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